Alphatec Holdings, Inc. (ATEC) Stock Rating Lowered by ValuEngine

Alphatec Holdings, Inc. (NASDAQ:ATEC) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report released on Thursday.

Separately, HC Wainwright initiated coverage on shares of Alphatec Holdings in a research report on Monday, August 14th. They issued a “buy” rating and a $4.00 price target for the company.

Alphatec Holdings (ATEC) opened at 1.92 on Thursday. The stock’s 50 day moving average price is $1.73 and its 200-day moving average price is $2.28. Alphatec Holdings has a 12 month low of $1.58 and a 12 month high of $9.65.

Alphatec Holdings (NASDAQ:ATEC) last released its quarterly earnings data on Thursday, August 10th. The medical technology company reported ($0.32) earnings per share (EPS) for the quarter. The firm had revenue of $24.38 million for the quarter. Equities research analysts predict that Alphatec Holdings will post ($1.20) EPS for the current fiscal year.

WARNING: “Alphatec Holdings, Inc. (ATEC) Stock Rating Lowered by ValuEngine” was first published by BNB Daily and is the property of of BNB Daily. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at

A hedge fund recently raised its stake in Alphatec Holdings stock. Broadfin Capital LLC increased its position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 163.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 594,533 shares of the medical technology company’s stock after buying an additional 368,527 shares during the period. Broadfin Capital LLC’s holdings in Alphatec Holdings were worth $1,100,000 as of its most recent SEC filing. 20.69% of the stock is currently owned by hedge funds and other institutional investors.

About Alphatec Holdings

Alphatec Holdings, Inc is a medical technology company. The Company through its subsidiary, Alphatec Spine, Inc and its subsidiaries, designs, develops, manufactures and markets products for the surgical treatment of spine disorders. Its product portfolio and pipeline addresses the cervical, thoracolumbar and intervertebral regions of the spine and covers a range of spinal disorders and surgical procedures.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Alphatec Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec Holdings Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply